Compare DBRG & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBRG | ITGR |
|---|---|---|
| Founded | 1991 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2009 | 2000 |
| Metric | DBRG | ITGR |
|---|---|---|
| Price | $14.29 | $69.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $16.79 | ★ $92.86 |
| AVG Volume (30 Days) | ★ 5.6M | 623.1K |
| Earning Date | 10-30-2025 | 10-23-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.06 | ★ 2.42 |
| Revenue | $100,346,000.00 | ★ $1,831,074,000.00 |
| Revenue This Year | N/A | $9.69 |
| Revenue Next Year | $191.07 | $0.48 |
| P/E Ratio | $131.07 | ★ $28.71 |
| Revenue Growth | N/A | ★ 9.54 |
| 52 Week Low | $6.41 | $62.00 |
| 52 Week High | $14.84 | $146.36 |
| Indicator | DBRG | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 76.28 | 39.43 |
| Support Level | $9.44 | $69.40 |
| Resistance Level | $9.78 | $73.19 |
| Average True Range (ATR) | 0.66 | 1.75 |
| MACD | 0.40 | 1.12 |
| Stochastic Oscillator | 90.33 | 49.66 |
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.